Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2026
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 February 2026
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 October 2025
Sparsentan for treating primary IgA nephropathy (TA1074)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 9 October 2025Published: 25 June 2025
Dapagliflozin for treating chronic kidney disease (TA1075)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 July 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2025
Empagliflozin for treating chronic kidney disease (TA942)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Difelikefalin for treating pruritus in people having haemodialysis (TA890)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Immunosuppressive therapy for kidney transplant in adults (TA481)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 January 2009
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 June 2026
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sibeprenlimab for treating IgA nephropathy [ID6604]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Atrasentan for treating primary IgA nephropathy [ID6558]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating primary IgA nephropathy [ID6640]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for treating primary IgA nephropathy [ID6703]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating primary membranous nephropathy [ID6751]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC